BENGALURU, India September 22, 2020
Biocon Limited (BSE: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, announced today that Anupam Jindal Chief Financial Officer (CFO). Anupam will head the finance function at Biocon and be part of the Executive Leadership Team. He will repo hief Executive Officer & Managing Director, Siddharth Mittal.
Prior to joining Biocon, Anupam worked with the Vedanta Group of companies for 22 years, where he held the position of Group Chief Financial Officer at Sterlite Technologies Limited since 2006. Anupam played a key role in growing the company’s revenue exponentially through organic capacity expansion and acquisitions, in India and abroad. He was also instrumental in driving several strategic initiatives, such as inception and growth of new business verticals.
Anupam holds a Bachelor of Commerce (B Com) degree from ML Sukhadia University, Udaipur. He is also a Chartered Accountant from the Institute of Chartered Accountants of India and a Company Secretary from the Institute of Company Secretaries of India
Biocon’s Chief Executive Officer and Managing Director, Siddharth Mittal said, “We are pleased to have Anupam join us at this crucial phase of our growth, as we expand our portfolio and enter new geographies, to address patient needs for affordable, high-quality medicines. With his proven track record of steering high-growth companies, Anupam will play a key role in helping deliver on our business goals “
About Biocon Limited
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development.